Mesenchymal Cell News Volume 3.09 | Mar 8 2011

    0
    24

    Mesenchymal Cell News 3.09, March 8, 2011.

         In this issue: Science News | Current Publications | Industry News | Policy News | Events
     

    TOP STORY

    Lentiviral Vector Mediated Modification of Mesenchymal Stem Cells and Enhanced Survival in an In Vitro Model of Ischemia
    Researchers investigated lentiviral vector-mediated genetic modification of rat bone-marrow derived mesenchymal stem cells and examined any functional effect of such genetic modification in an in vitro model of ischemia. [Stem Cell Res Ther]

    Aldefluor_645x110_v01.jpg

    SCIENCE NEWS
    Newborn Heart Muscle Can Grow Back by Itself
    In a promising science-fiction-meets-real-world juxtaposition, researchers have discovered that the mammalian newborn heart can heal itself completely. [Press release from The University of Texas Southwestern Medical Center discussing online prepublication in Science]

    Human Stem Cells from Fat Tissue Fuse with Rat Heart Cells and Beat
    According to new research, scientists have successfully fused human stem cells derived from subcutaneous adipose tissue with muscle cells from rat hearts. Not only did these cells “talk” to form new muscle cells altogether, but they actually beat. [Press release from EurekAlert! discussing online prepublication in the FASEB Journal]

    Biomimetic Patch to Be Tested on Tricky Tendon-to-Bone Repairs
    Two Washington scientists are imitating nature as they attempt to solve one of the most difficult problems in orthopedic surgery: reattaching tendon to bone. [Washington University in St. Louis Press Release]

    ON106-MethoCultWallchart-645x110.jpg

    CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

    Transient Regenerative Potential of the Neonatal Mouse Heart
    Researchers found that the hearts of 1-day-old neonatal mice can regenerate after partial surgical resection, but this capacity is lost by 7 days of age. [Science]

    Wnt Signaling Promotes Neuronal Differentiation from Mesenchymal Stem Cells Through Activation of Tlx3
    Since neurons in cranial sensory ganglia and dorsal root ganglia transiently express Ngn1, NeuroD and Brn3a during embryonic development, researchers hypothesized that Wnt proteins could instructively promote a sensory neuronal fate from mesenchymal stem cells directed to differentiate into neurons. [Stem Cells]

    The Promotion of Cartilage Defect Repair Using Adenovirus Mediated Sox9 Gene Transfer of Rabbit Bone Marrow Mesenchymal Stem Cells
    The chondrogenic effect of Sox9 on bone marrow mesenchymal stem cells in vitro and its application in articular cartilage repair in vivo were evaluated. [Biomaterials]

    Human Adipose Tissue-Derived Stem Cells Exhibit Proliferation Potential and Spontaneous Rhythmic Contraction After Fusion with Neonatal Rat Cardiomyocytes
    This study illustrates that human adipose tissue-derived stem cells exhibit both stem cell (proliferation) and cardiomyocyte properties (action potential and spontaneous rhythmic beating) after fusion with rat cardiomyocytes, supporting the theory that fusion, even if artificially induced, could indeed be a mechanism for cardiomyocyte renewal in the heart. [FASEB J]

    The Cdc42 Guanine Nucleotide Exchange Factor FGD1 Regulates Osteogenesis in Human Mesenchymal Stem Cells
    Results demonstrate an important role for FGD1/Cdc42 signaling in human mesenchymal stem cell osteogenesis and suggest that the defects in bone remodeling in faciogenital dysplasia may persist throughout adult life and serve as a potential pathway that may be targeted for enhancing bone regeneration. [Am J Pathol]

    fMLP Promotes Osteoblast Differentiation via the N-Formyl Peptide Receptor 1-Mediated Signaling Pathway in Human Mesenchymal Stem Cells from Bone Marrow
    Findings provide novel insight into the functional role of N-formyl-methionyl-leucyl-phenylalanine (fMLP) in bone biology, with important implications for its potential use as a therapeutic agent for treatment of bone-related disorders. [J Biol Chem]

    Comparison of Canine Umbilical Cord Blood-Derived Mesenchymal Stem Cell Transplantation Times: Involvement of Astrogliosis, Inflammation, Intracellular Actin Cytoskeleton Pathways, and Neurotrophin
    Transplantation of canine mesenchymal stem cells one week after spinal cord injury was more effective in improving clinical signs and neuronal regeneration and reducing fibrosis formation compared to the other transplantation times evaluated. [Cell Transplant]

    MicroRNA 21 Regulates the Proliferation of Human Adipose Tissue-Derived Mesenchymal Stem Cells and High-Fat Diet-Induced Obesity Alters MicroRNA 21
    Researchers determined the expression of microRNA-21 (miR-21) in white adipose tissues in a high-fat diet-induced obesity mouse model to examine the relationship between miR-21 and obesity and the effect of miR-21 on human adipose tissue-derived mesenchymal stem cell proliferation. [J Cell Physiol]

    Hyaline Cartilage Regeneration by Combined Therapy of Microfracture and Long-Term BMP-2 Delivery
    Researchers tested the hypothesis that long-term delivery of bone morphogenetic protein (BMP)-2 to cartilage defects subjected to microfracture results in regeneration of high quality hyaline-like cartilage, as opposed to short-term delivery of BMP-2 or no BMP-2 delivery. [Tissue Eng Part A]

    Epithelial Interactions and Local Engraftment of Lung-Resident Mesenchymal Stem Cells
    This study demonstrates, for the first time, an ability of tissue-specific mesenchymal stem cells to engraft in their organ of origin and establishes a pathway of bi-directional interaction between these mesenchymal progenitors and adult somatic epithelial cells in the lung. [Am J Respir Cell Mol Biol]

    Gingiva-Derived Mesenchymal Stem Cells-Mediated Therapeutic Approach for Bone Tissue Regeneration
    Results imply that mesenchymal stem cells derived from gingival tissue could be a novel source for stem cell-based therapy in bone reconstruction in clinical applications. [Stem Cells Dev]

    INDUSTRY NEWS
    Yissum and Hadasit License Regenerative Polymeric Membrane Implants to RegeneCure
    Yissum Research Development Company Ltd. and Hadasit Medical Research Services & Development Ltd. announced that they have licensed innovative regenerative membrane implant technology to RegeneCure, which will further develop and commercialize the technology for bone tissue engineering for applications in trauma, spine, and reconstructive cranial and facial orthopedics. [BusinessWire]

    Positive Pre-Clinical Data from Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical Indication
    Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies, in cooperation with the Charité – University of Medicine in Berlin, announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. [Pluristem Therapeutics, Inc. Press Release]

    New Breast Reconstruction Procedure Demonstrates Long Term Success in European Trial; Data Reported from Cytori’s Restore-2 Study of the Celution® System
    Results from a European breast reconstruction trial using a new minimally invasive procedure to repair lumpectomy defects resulted in a sustained and substantial rate of physician and patient satisfaction at 12 months. The study utilized the regenerative cells in the patient’s own fat tissue, extracted at the time of the procedure using the Celution® 800/CRS System. [Cytori Therapeutics, Inc. Press Release]

    Osiris Therapeutics Completes Enrollment of Stem Cell Trial for the Treatment of Heart Attacks
    Osiris Therapeutics, Inc. announced that it has successfully completed enrollment in a Phase II clinical trial evaluating Prochymal (remestemcel‐L), an adult mesenchymal stem cell therapy, in patients experiencing their first heart attack. [Osiris Therapeutics, Inc. Press Release]

    Case Western Reserve Positions Regenerative Medicine Center for Future Growth
    In a move to streamline and accelerate the research and development of new stem cell and regenerative medicine technologies, the National Center for Regenerative Medicine and the Center for Stem Cell and Regenerative Medicine at Case Western Reserve University have been rolled into a single entity housed within the university’s School of Medicine. [Case Western Reserve University Press Release]

    Mesoblast Half-Year Results
    Regenerative medicine company Mesoblast Limited reported its half year results for the period ended 31 December 2010. [Mesoblast Limited Press Release]

    POLICY NEWS

    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS

    Advances in Stem Cell Research: Development, Regeneration and Disease
    April 6-8, 2011
    Paris, France

    2nd Annual Translational Regenerative Medicine Forum
    April 6-8, 2011
    Washington, DC, Untied States

    3rd Meeting of the Forum of Italian Researchers on Mesenchymal and Stromal Stem Cells (FIRST)
    April 18, 2011
    Milan, Italy

    Stem Cells for Drug Developers 2011
    April 26-29, 2011
    Boston, United States

    Israeli Stem Cells Society 4th Annual Meeting 2011
    May 23-24, 2011
    Tel-Hashomer, Israel

    BioBanking
    July 11-12, 2011
    London, United Kingdom

    Stem Cell Programming & Reprogramming
    December 8-11, 2011
    Lisbon, Portugal

    Visit our events page to see a complete list of events in the mesenchymal cell community.

    JOB OPPORTUNITIES

    Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

    Assistant Professor (University of Pittsburgh School of Medicine, Center for Cellular and Molecular Engineering)

    Field Applications Specialist – Cell Therapy (Pall Corporation) 

    Postdoctoral Position – Scientist (Helmholtz Zentrum München – German Research Center for Environmental Health – Helmholtz Association)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities with the Connexon Creative Job Board at no cost.

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Mesenchymal Cell News: Archives | Events | Contact Us